Clinical research
The Janssen Pharmaceutical Companies of Johnson & Johnson announced multiple data presentations from its solid tumour portfolio, including key prostate cancer data, will be featured at the European Society for Medical Oncology 2019 Annual Congress, taking place 27th September to 1st October in Barcelona, Spain.
Company’s insulin-based Imotope™ IMCY-0098 shows excellent safety profile and promising clinical trends
Shares of Zealand Pharma A/S are climbing in premarket trading after the company posted another late-stage success for dasiglucagon in treating severe hypoglycemia.
RESCUE and REVERSE are two separate but parallel Phase III trials evaluating the efficacy of a single intravitreal injection of GS0101 in patients with LHON from the G11778A mutation in the mitochondrial ND4 gene.
Ipsen announced positive data from the ENGAGE Phase IIIb/IV clinical trial of Dysport (abobotulinumtoxinA) to treat upper and lower limb spasticity in adults with a Guided Self-rehabilitation Contract.
Last week was an unusually busy week for clinical trial news, with numerous companies presenting results at conferences. Here’s a look at the top stories.
While the Danish drugmaker’s Tresiba (insulin degludec) didn’t fare as well as hoped in the head-to-head trial, Novo Nordisk was quick to point out that Tresiba showed an overall lower risk of hypoglycemia compared to Toujeo.
While the approval of AveXis’ gene therapy for spinal muscular atrophy has been tainted by the revelation of early data manipulation, the Novartis subsidiary presented some long-term data at a conference that backs up the treatment’s efficacy.
AveXis presented new interim data from the Phase III SPR1NT trial of Zolgensma (onasemnogene abeparvovec-xioi) in spinal muscular atrophy (SMA) Type 1.
Primary results showed significantly greater reduction in blood sugar levels over 26 weeks after switching to Soliqua® / Suliqua® 1 vs staying on daily or weekly GLP-1 receptor agonist
PRESS RELEASES